Emergent Biosolutions Inc (NYSE: EBS) is -50.63% lower on its value in year-to-date trading and has touched a low of $1.82 and a high of $15.10 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The EBS stock was last observed hovering at around $4.54 in the last trading session, with the day’s gains setting it 0.18%.
Currently trading at $4.72, the stock is 0.28% and -22.44% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.09 million and changing 3.96% at the moment leaves the stock -44.88% off its SMA200. EBS registered 153.76% gain for a year compared to 6-month loss of -48.36%. The firm has a 50-day simple moving average (SMA 50) of $6.086 and a 200-day simple moving average (SMA200) of $8.5633.
The stock witnessed a -17.48% gain in the last 1 month and extending the period to 3 months gives it a -53.82%, and is 3.06% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.88% over the week and 9.11% over the month.
Emergent Biosolutions Inc (EBS) has around 900 employees, a market worth around $256.47M and $1.04B in sales. Profit margin for the company is -18.26%. Distance from 52-week low is 158.72% and -68.74% from its 52-week high. The company has generated returns on investments over the last 12 months (-16.49%).
with sales reaching $218.5M over the same period.The EPS is expected to grow by 426.09% this year, but quarterly earnings will post -12.32% year-over-year. Quarterly sales are estimated to shrink -27.26% in year-over-year returns.
Emergent Biosolutions Inc (EBS) Top Institutional Holders
192.0 institutions hold shares in Emergent Biosolutions Inc (EBS), with institutional investors hold 65.63% of the company’s shares. The shares outstanding are 54.30M, and float is at 52.32M with Short Float at 17.15%. Institutions hold 64.14% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 3.84 million shares valued at $26.18 million. The investor’s holdings represent 7.2992% of the EBS Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 3.67 million shares valued at $25.0 million to account for 6.97 of the shares outstanding. The other top investors are CHARLES SCHWAB INVESTMENT MANAGEMENT INC which holds 3.17 million shares representing 6.0195% and valued at over $21.59 million, while MORGAN STANLEY holds 2.3615 of the shares totaling 1.24 million with a market value of $8.47 million.
Emergent Biosolutions Inc (EBS) Insider Activity
The most recent transaction is an insider sale by Fowler Neal Franklin, the company’s Director. SEC filings show that Fowler Neal Franklin sold 35,000 shares of the company’s common stock on Mar 12 ’25 at a price of $5.83 per share for a total of $0.2 million. Following the sale, the insider now owns 0.1 million shares.
Emergent Biosolutions Inc disclosed in a document filed with the SEC on Mar 12 ’25 that Zoon Kathryn C (Director) sold a total of 10,000 shares of the company’s common stock. The trade occurred on Mar 12 ’25 and was made at $5.73 per share for $57300.0. Following the transaction, the insider now directly holds 44482.0 shares of the EBS stock.
Still, SEC filings show that on Mar 12 ’25, Fowler Neal Franklin (Director) Proposed Sale 35,000 shares at an average price of $5.83 for $0.2 million. The insider now directly holds shares of Emergent Biosolutions Inc (EBS).
